ASPP1 and ASPP2: common activators of p53 family members.

Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev (2006) 2.23

p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07

ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer (2007) 1.94

The p53 family and programmed cell death. Oncogene (2008) 1.81

Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61

Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene (2008) 1.57

ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev (2006) 1.49

Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep (2013) 1.43

Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol (2006) 1.37

Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32

A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest (2007) 1.27

DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell (2012) 1.27

Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A (2009) 1.25

P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene (2011) 1.22

Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63. Nucleic Acids Res (2006) 1.13

Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11

Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem (2009) 1.09

Tied up in loops: positive and negative autoregulation of p53. Cold Spring Harb Perspect Biol (2009) 1.05

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ (2013) 1.05

Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res (2008) 1.03

Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinone oxidoreductase PIG3. J Biol Chem (2009) 1.02

iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer (2010) 1.02

Decision Making by p53: Life versus Death. Mol Cell Pharmacol (2010) 1.01

N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence. Proc Natl Acad Sci U S A (2012) 1.00

Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc Natl Acad Sci U S A (2011) 0.99

Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression. Nucleic Acids Res (2006) 0.97

CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2. Cell Death Dis (2014) 0.96

ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A (2013) 0.94

Interleukin-8 is the single most up-regulated gene in whole genome profiling of H. pylori exposed gastric epithelial cells. BMC Microbiol (2012) 0.93

ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. Nat Cell Biol (2014) 0.92

Apoptosis and disease: a life or death decision. EMBO Rep (2004) 0.90

p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90

Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res (2008) 0.86

Structural basis for ASPP2 recognition by the tumor suppressor p73. J Mol Biol (2012) 0.83

A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene (2014) 0.83

Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells. Front Physiol (2016) 0.83

AMPK couples p73 with p53 in cell fate decision. Cell Death Differ (2014) 0.83

CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. J Med Primatol (2011) 0.82

iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy (ARVC)-induced sudden death. Proc Natl Acad Sci U S A (2015) 0.80

ASPP2 links the apical lateral polarity complex to the regulation of YAP activity in epithelial cells. PLoS One (2014) 0.80

Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. Oncotarget (2015) 0.80

Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif. Biochem Biophys Res Commun (2014) 0.80

NAD(P)H quinone oxidoreductase protects TAp63gamma from proteasomal degradation and regulates TAp63gamma-dependent growth arrest. PLoS One (2010) 0.80

Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. Future Oncol (2010) 0.80

An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence. EMBO J (2011) 0.79

Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines. Cancer Cell Int (2013) 0.78

Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer (2015) 0.78

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS One (2015) 0.78

p73-Binding Partners and Their Functional Significance. Int J Proteomics (2011) 0.78

Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is required for neuronal survival after axonal injury. PLoS One (2014) 0.78

Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PLoS One (2013) 0.77

Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. Chin Med (2013) 0.77

Highly homologous proteins exert opposite biological activities by using different interaction interfaces. Sci Rep (2015) 0.77

ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold. PLoS One (2016) 0.76

ASPP1/2-PP1 complexes are required for chromosome segregation and kinetochore-microtubule attachments. Oncotarget (2015) 0.75

Transcriptional Response to Acute Thermal Exposure in Juvenile Chinook Salmon Determined by RNAseq. G3 (Bethesda) (2015) 0.75

Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73. Oncogene (2015) 0.75

Downregulation of inhibitor of apoptosis‑stimulating protein of p53 inhibits proliferation and promotes apoptosis of gastric cancer cells. Mol Med Rep (2015) 0.75

iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancer Res (2017) 0.75

ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome. Cell Death Differ (2016) 0.75

Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis (2016) 0.75

MiR-187 overexpression inhibits cervical cancer progression by targeting HPV16 E6. Oncotarget (2017) 0.75

Surfing the p53 network. Nature (2000) 35.36

A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21

Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26

Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48

Regulation of p53 stability by Mdm2. Nature (1997) 18.20

Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54

Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27

p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33

Recruitment of p300/CBP in p53-dependent signal pathways. Cell (1997) 5.10

ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38

On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57

Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50

Mdm2 binds p73 alpha without targeting degradation. Oncogene (1999) 1.62

Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol (1998) 1.51

Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene (1999) 1.26

The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem (2001) 1.22

The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol (2000) 1.12

The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J Gen Virol (1998) 0.97

p300 does not require its acetylase activity to stimulate p73 function. J Biol Chem (2001) 0.97

Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J (2003) 0.94

Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. J Biol Chem (2000) 0.88

p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. Oncogene (2001) 0.87

Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47

The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82

Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31

X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17

Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01

Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04

Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89

Improved response to disasters and outbreaks by tracking population movements with mobile phone network data: a post-earthquake geospatial study in Haiti. PLoS Med (2011) 4.38

Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med (2013) 4.35

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80

The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61

Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36

A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13

Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08

Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res (2007) 3.05

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76

PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58

Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54

Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53

Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49

RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol (2003) 2.46

iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41

Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. Arch Intern Med (2011) 2.41

Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32

Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29

Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29

Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27

The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol (2011) 2.23

A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol (2008) 2.22

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08

A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95

The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94

The association between hospital obstetrical volume and maternal postpartum complications. Am J Obstet Gynecol (2012) 1.90

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90

The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75

Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A (2010) 1.70

ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell (2010) 1.68

Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64

Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res (2013) 1.58

Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem (2012) 1.58

Forceps delivery volumes in teaching and nonteaching hospitals: are volumes sufficient for physicians to acquire and maintain competence? Acad Med (2014) 1.55

The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol (2011) 1.55

Female ground tits prefer relatives as extra-pair partners: driven by kin-selection? Mol Ecol (2011) 1.54

A boosting approach for motif modeling using ChIP-chip data. Bioinformatics (2005) 1.53

The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev (2010) 1.50

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50

Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta (2009) 1.50

Insurance status and the transfer of hospitalized patients: an observational study. Ann Intern Med (2014) 1.49

ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev (2006) 1.49

Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Cell Cycle (2010) 1.47

Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis (2005) 1.46

To die or not to die: how does p53 decide? Oncogene (2004) 1.45

Predicting network activity from high throughput metabolomics. PLoS Comput Biol (2013) 1.44

A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43

Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta (2008) 1.43

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42

Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest (2011) 1.42

Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41

Adverse outcomes in hip arthroplasty: long-term trends. J Bone Joint Surg Am (2012) 1.40

RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J Proteome Res (2008) 1.40

The impact of hospital cardiac specialization on outcomes after coronary artery bypass graft surgery: analysis of medicare claims data. Circ Cardiovasc Qual Outcomes (2010) 1.39

ASPP [corrected] and cancer. Nat Rev Cancer (2006) 1.38

Intrauterine administration of endotoxin leads to motor deficits in a rabbit model: a link between prenatal infection and cerebral palsy. Am J Obstet Gynecol (2008) 1.36

Struma ovarii associated with pseudo-Meigs' syndrome and elevated serum CA 125: a case report and review of the literature. J Ovarian Res (2010) 1.36

Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35

Intrahepatic biliary cystadenoma and cystadenocarcinoma: an experience of 30 cases. Dig Liver Dis (2011) 1.35

MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep (2011) 1.34

Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A (2012) 1.31

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood (2005) 1.31

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30

The p53 network in head and neck cancer. Oral Oncol (2003) 1.30

Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet (2009) 1.29

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28

Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem (2002) 1.28

Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2010) 1.27

A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest (2007) 1.27